On September 15, the 2026 China Pharmaceutical Industry Development Conference opened in Zhongshan, Guangdong Province, co-hosted by the SME Development Promotion Center of the Ministry of Industry and Information Technology, the Department of Industry and Information Technology of Guangdong Province, and the Zhongshan Municipal People's Government. At the conference, ICBC officially unveiled the "ICBC Kangrong 鈥?Comprehensive Financial Solution for the Biopharmaceutical Industry," designed to address the diverse financial needs across the biopharmaceutical value chain, establishing a full-cycle, full-chain specialized service system to continuously channel financial support into innovative development within the sector.

For domestic pharmaceutical enterprises, ICBC leverages its technology-finance ecosystem service platform to support startups in preclinical R&D and result incubation. For growth-stage companies, it focuses on key milestones such as clinical trials and pilot-scale amplification to ensure the steady advancement of R&D pipelines. In the commercialization phase, it assists mature enterprises with capacity expansion, technological upgrades, global layout, and industrial consolidation. During corporate transformation, it utilizes tools like acquisition loans to help businesses optimize debt structures and revitalize existing assets.

For multinational pharmaceutical companies, ICBC provides integrated services including global pool structures, exchange rate risk hedging, medium- and long-term financing, and localized supply chain coordination, enabling these firms to deepen their integration into the domestic industrial ecosystem and expand their R&D, production, and investment activities in China. Concurrently, addressing various scenarios across the biopharmaceutical supply chain, ICBC consolidates group resources to deliver comprehensive financial products such as financing, investment banking, treasury management, settlement, and cross-border services, supplemented by equity incentive and compensation management offerings, while strengthening industrial resource matchmaking.

Looking ahead, ICBC will continue to enrich its financing, advisory, technology, and connectivity services, deepen its comprehensive financial solutions, and foster innovation, supply chain synergy, and international collaboration within the biopharmaceutical industry, making greater contributions to accelerating the construction of a Healthy China.